Etzioni R - Search Results

1

Short-term Endpoints for Cancer Screening Trials: Does Tumor Subtype Matter?

Owens L, Gogebakan KC, Menon U, Gulati R, Weiss NS, Etzioni R. Owens L, et al. Among authors: etzioni r. Cancer Epidemiol Biomarkers Prev. 2023 Jun 1;32(6):741-743. doi: 10.1158/1055-9965.EPI-22-1307. Cancer Epidemiol Biomarkers Prev. 2023. PMID: 37259797 Free PMC article.

2

Androgen receptor polymorphisms and the incidence of prostate cancer.

Chen C, Lamharzi N, Weiss NS, Etzioni R, Dightman DA, Barnett M, DiTommaso D, Goodman G. Chen C, et al. Among authors: etzioni r. Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1033-40. Cancer Epidemiol Biomarkers Prev. 2002. PMID: 12376504

3

Estimating the influence of rescreening interval on the benefits associated with cancer screening: approaches and limitations.

Weiss NS, Etzioni R. Weiss NS, et al. Among authors: etzioni r. Epidemiology. 2002 Nov;13(6):713-7. doi: 10.1097/00001648-200211000-00017. Epidemiology. 2002. PMID: 12410014 Review.

4

Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer.

Lamharzi N, Johnson MM, Goodman G, Etzioni R, Weiss NS, Dightman DA, Barnett M, DiTommaso D, Chen C. Lamharzi N, et al. Among authors: etzioni r. Int J Cancer. 2003 Jul 1;105(4):480-3. doi: 10.1002/ijc.11126. Int J Cancer. 2003. PMID: 12712437 Free article.

5

Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial.

Chen C, Weiss NS, Stanczyk FZ, Lewis SK, DiTommaso D, Etzioni R, Barnett MJ, Goodman GE. Chen C, et al. Among authors: etzioni r. Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1410-6. Cancer Epidemiol Biomarkers Prev. 2003. PMID: 14693730

6

Case-control studies of the efficacy of cancer screening: overcoming bias from nonrandom patterns of screening.

Weiss NS, Dhillon PK, Etzioni R. Weiss NS, et al. Among authors: etzioni r. Epidemiology. 2004 Jul;15(4):409-13. doi: 10.1097/01.ede.0000129518.99816.e1. Epidemiology. 2004. PMID: 15232400

7

Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: do combination tests improve detection?

Etzioni R, Falcon S, Gann PH, Kooperberg CL, Penson DF, Stampfer MJ. Etzioni R, et al. Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1640-5. Cancer Epidemiol Biomarkers Prev. 2004. PMID: 15466981 Clinical Trial.

8

An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States.

Shaw PA, Etzioni R, Zeliadt SB, Mariotto A, Karnofski K, Penson DF, Weiss NS, Feuer EJ. Shaw PA, et al. Among authors: etzioni r. Am J Epidemiol. 2004 Dec 1;160(11):1059-69. doi: 10.1093/aje/kwh336. Am J Epidemiol. 2004. PMID: 15561985

9

Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.

Telesca D, Etzioni R, Gulati R. Telesca D, et al. Among authors: etzioni r. Biometrics. 2008 Mar;64(1):10-9. doi: 10.1111/j.1541-0420.2007.00825.x. Epub 2007 May 14. Biometrics. 2008. PMID: 17501937

10

Quantifying the role of PSA screening in the US prostate cancer mortality decline.

Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, DiTommaso D, Karnofski K, Gulati R, Penson DF, Feuer E. Etzioni R, et al. Cancer Causes Control. 2008 Mar;19(2):175-81. doi: 10.1007/s10552-007-9083-8. Epub 2007 Nov 20. Cancer Causes Control. 2008. PMID: 18027095 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

284 results

Search Page